What is Gadoxetate disodium used for?

GADOXETATE (gad OX e tate) is a contrast agent. It is used to diagnose abnormalities during a MRI.

Why is primovist used?

Primovist is a contrast medium for magnetic resonance imaging (MRI) of the liver. It is used to help detect and diagnose changes that may be found in the liver. Abnormal signs within the liver can be better evaluated as to number, size, and distribution.

Why is Eovist used?

Eovist® (gadoxetate disodium) injection is indicated for intravenous use in magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in patients with known or suspected focal liver disease.

Is Eovist a gadolinium?

EOVIST® Injection is a gadolinium-based contrast agent indicated for intravenous use in T1 weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

What is focal nodular hyperplasia?

Focal nodular hyperplasia (FNH) is a benign liver lesion that is composed of a proliferation of hyperplastic hepatocytes surrounding a central stellate scar. Typically, FNH is a solitary lesion that is more commonly seen in women.

Is Eovist safe?

Clinical trials have shown that Eovist Injection can be administered as a bolus injection without significant safety concerns and without clinically relevant effects on vital signs. [9,10] Also, laboratory data revealed no relevant changes in blood or urinary parameters after administration of Eovist Injection.

Is primovist a gadolinium?

Gadoxetate disodium (also known by the tradenames PrimovistTM and EovistTM) is a hepatospecific paramagnetic gadolinium-based contrast agent, used exclusively in MRI liver imaging. Its chief use is in hepatic lesion characterization, i.e. assessing focal liver lesions identified on other imaging studies.

What is a focal nodule?

What is the difference between gadavist and Eovist?

Gadavist (gadobutrol) and Eovist (gadoxetate disodium) are available as sterile solutions for injection and are administered intravenously. Structurally, Gadavist is a macrocyclic gadolinium-based contrast agent (GBCA), and Eovist is a linear GBCA.

Is nodular hyperplasia cancerous?

What Is Focal Nodular Hyperplasia (FNH)? FNH is a benign tumor, or lesion, that forms in the liver. These tumors are not cancer.

Should FNH be removed?

Thus FNH is often found incidentally on health screening. If symptoms are present, appropriate conservative treatment should be performed. Surgical resection can be considered if symptoms persist or if imaging findings are difficult to distinguish from other diseases requiring surgical treatment.

Is Eovist safe for kidneys?

The administration of contrast agents that contain gadolinium such as Primovist/Eovist might increase a potential risk to develop a rare condition called nephrogenic systemic fibrosis (NSF) in patients with renal impairment.

What is Eovist contrast?

Eovist is a contrast agent that has magnetic properties. It is used in combination with magnetic resonance imaging (MRI) to allow blood vessels, organs, and other non-bony tissues to be seen more clearly. Eovist is used to help diagnose certain disorders of the liver.

What makes a tumor benign?

It is caused by cells dividing more than normal or not dying when they should. Tumors can be classified as benign or malignant. Benign tumors are those that stay in their primary location without invading other sites of the body. They do not spread to local structures or to distant parts of the body.

Is gadolinium used in Europe?

Most gadolinium-containing contrast agents have been authorised nationally in the EU. OptiMARK (gadoversetamide) is the only gadolinium contrast agent that was authorised centrally via EMA in the EU.

Is gadavist the same as gadolinium?

Gadavist is a prescription medicine called a gadolinium-based contrast agent (GBCA).

What causes Nodular Hyperplasia?

Unlike the most common liver mass which is the hemangioma, focal nodular hyperplasia is thought to be the result of increased hepatocyte number caused by hypoperfusion or hyperperfusion from anomalous arteries within the hepatic lobule.

Can focal nodular hyperplasia be removed?

If the FNH is large, surgeons may remove the tumor. In partial hepatectomy surgery, or resection, surgeons extract the tumor and a small part of the tissue around it.

Can FNH turn malignant?

FNH has no malignant potential, is rarely symptomatic and surgical intervention is almost never required. However, eight patients with a diagnosis of FNH associated with upper abdominal pain or rapid growth were referred for surgery.

What causes FNH to grow?

The underlying mechanism of FNH formation is thought to be due to a vascular malformation and injury [5]. Patients do not have an underlying liver disease and are mostly asymptomatic [6]. With the current availability of highly sensitive imaging techniques, FNH is diagnosed more often as an incidental lesion.

What does gadoxetate disodium stand for?

Gadoxetate disodium. Gadoxetate disodium (also known by the tradenames PrimovistTM and EovistTM) is a hepatospecific paramagnetic gadolinium-based contrast agent, used exclusively in MRI liver imaging . Its chief use is in hepatic lesion characterization, i.e. assessing focal liver lesions identified on other imaging studies. Gadoxetic acid…

What percentage of gadoxetate disodium is in the liver?

Approximately 50% of an injected dose of gadoxetate disodium is taken up by the liver. The next strongest hepatobiliary agent is gadobenate dimeglumine (MultiHance), with only 5% of the injected dose taken up by the liver 2 .

Is gadoxetate disodium teratogenic during organogenesis?

Gadoxetate disodium was not teratogenic when given intravenously during organogenesis to pregnant rats at doses up to 32 times the recommended single human dose (mmol/m2 basis). However, an increase in preimplantation loss was noted at 3.2 times the human dose (mmol/m2 basis).

Is gadoxetate disodium safe to use during pregnancy?

Embryotoxicity occurred in pregnant rabbits that received daily gadoxetate disodium at 26 times the recommended human dose (mmol/m2 basis), and maternal toxicity occurred in pregnant rats at doses 32 times the human dose (mmol/m2 basis). EOVIST should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.